| __timestamp | BioMarin Pharmaceutical Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 91733000 |
| Thursday, January 1, 2015 | 402271000 | 87644000 |
| Friday, January 1, 2016 | 476593000 | 92365000 |
| Sunday, January 1, 2017 | 554336000 | 85656000 |
| Monday, January 1, 2018 | 604353000 | 88196000 |
| Tuesday, January 1, 2019 | 680924000 | 89971000 |
| Wednesday, January 1, 2020 | 737669000 | 93413000 |
| Friday, January 1, 2021 | 759375000 | 91355000 |
| Saturday, January 1, 2022 | 854009000 | 113676000 |
| Sunday, January 1, 2023 | 937300000 | 198366000 |
| Monday, January 1, 2024 | 1009025000 | 218935000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. BioMarin Pharmaceutical Inc. and Taro Pharmaceutical Industries Ltd. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, BioMarin's SG&A expenses surged by over 200%, reflecting its aggressive expansion and investment in new therapies. In contrast, Taro's expenses grew by approximately 116%, indicating a more conservative approach.
BioMarin's expenses peaked in 2023, reaching nearly 9.4 times its 2014 levels, while Taro's expenses, though increasing, remained more stable. This divergence highlights BioMarin's strategy of reinvestment and growth, compared to Taro's focus on efficiency and cost control. As we look to 2024, with some data yet to be reported, the pharmaceutical landscape continues to evolve, offering insights into strategic financial management.
Regeneron Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Taro Pharmaceutical Industries Ltd. and Celldex Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?